PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kennedy, P.T.* ; Allweiss, L.* ; Bertoletti, A.* ; Cornberg, M.* ; Gehring, A.J.* ; Guidotti, L.G.* ; Kerth, H.A. ; Lemoine, M.* ; Levrero, M.* ; Lim, S.G.* ; Tavis, J.E.* ; Testoni, B.* ; Tu, T.*

Scientific and medical evidence informing expansion of hepatitis B treatment guidelines.

Lancet Gastroenterol. Hepatol. 10, 941-951 (2025)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Chronic hepatitis B treatment relies on nucleoside or nucleotide analogue drugs that suppress hepatitis B virus (HBV) replication, normalise liver enzymes, and slow disease progression with excellent safety profiles. Treatment is not curative, and patients remain at risk of cirrhosis and hepatocellular carcinoma. Treatment guidelines have generally restricted antiviral therapy to individuals with high HBV DNA and elevated ALT or hepatic fibrosis, often requiring longitudinal testing that can be scarcely available in resource-limited settings. Consequently, fewer than 3% of people living with HBV infection are receiving antiviral therapy. Guidelines from China and WHO recently broadened access criteria to antiviral therapy, but there are people who fall outside these guidelines who could still benefit from treatment initiation. The pathological processes induced by HBV infection are still active in these patients. We present the benefits and risks of expanding treatment eligibility. We believe that the benefits of reduced hepatic damage and carcinogenic stimuli greatly outweigh the risks.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
0.000
0.000
2
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Closed Circular Dna; Regulatory T-cells; Immune-tolerant; Hepatocellular-carcinoma; Antiviral Therapy; Natural-history; Liver; Infection; Risk; Interferon
Language english
Publication Year 2025
HGF-reported in Year 2025
ISSN (print) / ISBN 2468-1253
e-ISSN 2468-1253
Journal The lancet : Gastroenterology & Hepatology
Quellenangaben Volume: 10, Issue: 10, Pages: 941-951 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place London
Institute(s) Institute of Virology (VIRO)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Immune Response and Infection
PSP Element(s) G-502700-003
DOI 10.1016/S2468-1253(25)00053-6
WOS ID 001584040800004
Scopus ID 105014653348
PubMed ID 40714040
Erfassungsdatum 2025-07-29
[➜Report correction]